Metrics to compare | RVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRVXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −2.4x | −0.2x | |
PEG Ratio | −0.19 | 0.02 | 0.00 | |
Price/Book | −0.2x | 3.3x | 2.6x | |
Price / LTM Sales | - | 3.7x | 2.8x | |
Upside (Analyst Target) | - | 373.0% | 60.9% | |
Fair Value Upside | Unlock | −6.0% | 9.5% | Unlock |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.